Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.  The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.  Choi (necrotic) responses were more commonly observed in patients treated at higher doses.  In addition, intravenous infusion of JX-594 was safe and well-tolerated.  These data were presented today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington DC.

"These data represent a significant milestone for the field of oncology and viral therapy as this is the first time that a viral or genetic product has demonstrated reproducible, biopsy-proven delivery to multiple solid tumor types following intravenous administration," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We look forward to extending our experience with IV JX-594 in our planned Phase 3 trial in patients with advanced liver cancer.  This pivotal trial will utilize both IV and targeted intratumoral injections of JX-594 to maximize potential patient benefit.  We expect to initiate this study in Q4 of 2010."

"JX-594 represents a promising potential treatment option for patients with multiple types of cancer.  As the first intravenous biological immunotherapy to demonstrate safety and tumor-specific delivery, JX-594 may add significantly to the armamentarium for many solid tumors," stated '/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Australian prostate cancer technology company Minomic ... prize recognising ,outstanding, science that uses its patented antibody. ... a novel prostate cancer diagnostic test known as MiCheck® ... taking out the peer-reviewed Australian Museum Eureka Science Prize ... This prize is awarded for ground breaking research ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 /PRNewswire/ ... today announced the intent of the National Institute of Allergy ... of Health (NIH) within the Department of Health and Human ... be held in the United States ... of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's new $100,000 waste ... energy process and continue to contribute to the sustainability of our natural resources. ... Energy process has been operating at their Mexico facility, Recicladora Temarry, for the ...
(Date:9/1/2015)... ... 02, 2015 , ... Spirax Sarco , the leader in products and ... Sarco Anytime. This platform, offering unique online ordering capabilities, is only available to ... Log on to Spirax Sarco Anytime and within minutes you can be making your ...
Breaking Biology Technology:Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Spirax Sarco Announces New Features to Anytime Platform 2
... S*BIO Pte Ltd and Tragara Pharmaceuticals Inc. today ... to Tragara to develop and commercialize its novel multi-kinase ... is eligible to receive up to US$112.5 million in ... milestone payments and up to double-digit royalties. Additionally, ...
... Education Virtual Lecture and Podcast for Healthcare ProfessionalsVOORHEES, N.J., ... infection (CDI) is critical for several reasons. The ... by increasing rates and more severe disease. In ... an expanding list of states across the United States ...
... SHANGHAI, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- ... ("China-Biotics," "the Company"), a leading Chinese ... marketing and,distribution of probiotics products, today ... has approved manufacturing certificates for the ...
Cached Biology Technology:S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 2S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 3Clostridium difficile Infection: Current Challenges and Controversies 2China-Biotics, Inc. Receives Manufacturing Certificate for New Products 2China-Biotics, Inc. Receives Manufacturing Certificate for New Products 3
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... of Technology (TU/e) in The Netherlands will award an ... the Institute for BioNanotechnology in Medicine, at Northwestern University, ... of TU/e, on Friday, 24 April 2009. Stupp (57) ... matter and applications for complex molecular systems in biomedical ...
... State University faculty members are among the 486 newly ... of Science (AAAS), a prestigious international scientific society. AAAS ... Allenby, Richard Creath, James Elser, Patricia Gober, Nancy Grimm, ... recognized Feb. 14 at the Fellows forum, during the ...
... researchers have been named AAAS Fellows by the American ... is bestowed on association members by their scientific peers. ... scientifically or socially distinguished efforts to advance science or ... George Kraus, director of the Institute ...
Cached Biology News:Samuel Stupp to receive honorary doctorate from TU/e 2Eight ASU faculty elected as AAAS Fellows 2Eight ASU faculty elected as AAAS Fellows 3Eight ASU faculty elected as AAAS Fellows 4American Association for the Advancement of Science honors four Iowa Staters 2
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... PCR Purification Kits provide rapid and efficient ... PCR products, and salts from PCR products ... provides two Binding Buffer options for ... can be performed in either single column ...
... transcripts with the translation boosting Cap 1 ... capped (versus 40% to 80% capped using ... 2 hours. mScript™ also features the Cap ... be up to 50% more efficient in ...
Biology Products: